RBC Capital Maintains Outperform on Moderna, Lowers Price Target to $125
Portfolio Pulse from Benzinga Newsdesk
RBC Capital analyst Luca Issi has maintained an 'Outperform' rating on Moderna (NASDAQ:MRNA) but lowered the price target from $180 to $125.
November 03, 2023 | 7:13 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Moderna's price target has been lowered from $180 to $125 by RBC Capital, though the 'Outperform' rating is maintained.
The lowering of the price target by RBC Capital indicates a potential decrease in the short-term value of Moderna's stock. However, the maintained 'Outperform' rating suggests that the stock is still expected to perform well relative to its peers.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100